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Abstract: Background: Malignant pleural mesothelioma (MPM) is an asbestos-associated tumor 
with poor prognosis and few therapeutic options. JQ1, a selective antagonist of BRD4, modulates 
transcription of oncogenes, including MPM chemoresistance-associated c-Myc and Fra-1.  
Objective: We investigated if JQ1 could enhance the efficacy of cisplatin against MPM.	  
Methods: The antiproliferative activity of cisplatin in combination with JQ1 was assessed on MPM 
cell lines representative of the cellular phenotypes of this tumor (epithelioid, sarcomatoid and bipha-
sic), and on one cisplatin resistant sub-line. The combination schedule was optimized adopting a 3D-
spheroid model. Drug combination effects were correlated with cell cycle distribution and senes-
cence-associated β-galactosidase positive cells. The expression of c-Myc and Fra-1 proteins and 
some apoptosis markers was assessed by immunoblotting and RT-qPCR. DNA damage and repair 
were evaluated by means of alkaline comet assay. 	  
Results: JQ1 in combination with cisplatin elicited additive or synergistic (superadditive) antiprolif-
erative effects on MPM cells, depending on the cell line. The combination showed tumor regression 
on the 3D-spheroid model. It induced increased apoptosis, along with decreased c-Myc and, some-
times, Fra-1 expression, JQ1 decreased cisplatin-induced DNA breaks in all MPM cells and 
increased senescence even in less proficient cells, thus enhancing the DNA damage response (DDR). 	  
Conclusion: The superadditive effect is due to c-Myc repression. The consequent DDR enhance-
ment lead to apoptosis induction and/or permanent growth arrest (senescence), depending on the 
MPM cellular context, leading to tumor regression. Thus, the pharmacological modulation of BET 
activity could represent a promising tool for future MPM therapy.  
Keywords: Malignant Mesothelioma, BET Bromodomain Inhibition, JQ1, Epigenetics, Platinum-based chemotherapy, c-Myc, 
Fra-1. 
1. INTRODUCTION 
Malignant pleural mesothelioma (MPM) is a tumor asso-
ciated to occupational and environmental exposure to asbes-
tos. Due to the long latency of MPM, estimated in 20-40 
years, the reduction of asbestos contamination achieved in 
many countries, including Italy, will unlikely modify in the 
short period the risk of developing MPM and other asbestos-
related diseases. Indeed, the incidence of this pathology, 
although relatively rare, is expected to show a maximum 
over the coming decade. MPM is a very aggressive form of 
cancer derived from the pleura mesothelium (80% of all 
mesotheliomas), pericardium and peritoneum. The majority 
of MPM patients are treated mainly to improve their quality 
of life, rather than prolong survival, since median life expec-
tation after diagnosis ranges from 9-17 months. The actual  
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approach to MPM treatment is multimodal (trimodal ther-
apy) i.e. the combination of surgery, adjuvant or neoadjuvant 
chemotherapy, and radiation [1]. 
The current standard first-line treatment for advanced and 
unresectable MPM is cisplatin (or carboplatin) and antifo-
late-based (pemetrexed or raltitrexed) combination therapy. 
Several target-specific approaches have been explored, with 
limited results [2].  
MPM is a tumor highly resistant to any drug. The pro-
longed exposure of mesothelium to asbestos likely induces 
high levels of ROS, either from the mineral itself and from 
the inclusive macrophages while trying to clear the tissue 
from the fibers. This prolonged inflammation leads to the 
selection of mutated cells characterized by high antioxidant, 
DNA-repair, and antiapoptotic armory, while the apoptotic 
pathways are mainly down-regulated [3, 4]. Accordingly, our 
in vitro MPM cell panel, composed of three cell lines repre-
sentative of the different histotypes BR95 (epithelioid), 
MG06 (mixed), MM98 (sarcomatoid) cell line, and a cis-
platin–resistant sub-line, MM98R, has previously shown 
marked chemoresistance [5]. In particular, the epithelioid 
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cell line was highly resistant to any Pt-based drugs [6-9] and 
did not undergo apoptosis [10]. 
Cisplatin is the archetypal DNA-damaging metal-drug: it 
gives intra- and inter-strand DNA adducts that inhibit both 
transcription and replication. The most abundant intrastrand 
Pt-DNA lesions are tolerated via by-pass DNA polymerases 
or repaired by the nucleotide excision repair (NER) pathway. 
The lesion is excised, leaving two single strand breaks 
(SSB), and the resulting gap is refilled [11]. The basal NER 
machinery efficiently repairs lesions without activating the 
DNA damage response (DDR) [12]. DDR is a crucial signal-
ing pathway, that in response to genetic insults, allows dam-
age recognition, activation of cell cycle checkpoints, and 
DNA repair [13,14]. DDR can lead to cell rescue by means 
of DNA repair, to permanent growth arrest, i.e. cell senes-
cence, or to cell death through apoptosis [14,15].  The less 
abundant Pt-interstrand-DNA adducts prompt the DDR [16]. 
In fact, they are processed to double strand breaks (DSB), 
that trigger PI3 kinases (as ATM) signaling.  
ATM expression is ruled by the E2F-1 transcription factor 
[17], a c-Myc target gene [18]. ATM is activated by oxidative 
stress-sensors as HO-1 [19]. Cisplatin treatment induces HO-1 
expression [20]. ATM phosphorylates the downstream players 
p53 and γH2AX and thus induces the DDR [13]. 
The transcription factor p53 responds to cellular stress  
regulating target genes able to induce cell cycle arrest, se-
nescence, DNA repair [21] (as GADD45 [22]) and apoptosis 
(as APAF-1 [23]). The latter protein plays a central role in 
apoptosis induction as it activates procaspase-9, the upstream 
step of effector caspases [24]. However, p53-dependent 
apoptotic checkpoint depends on DAPK1 [25], and the 
downstream activity of caspase-3, -7 and -9 is blocked by 
members of the inhibitor of apoptosis (IAPs) family, as 
XIAP and survivin. These proteins are upregulated in meso-
thelioma, leading to cell survival [26]. 
γH2AX foci are platforms for the accumulation of DNA 
damage response and repair factors to the DSB site [27]. 
Homologous recombination (HR) and non-homologous end 
joining (NHEJ) are the main DNA repair mechanisms of 
DSBs [28]. In particular, HR mediates cisplatin resistance 
and represents the target for new therapies [29].  
Cisplatin chemoresistance is directly linked to c-Myc [30], 
and c-Myc repression is synergistic with cisplatin in MPM 
treated cells [31]. The proto-oncogene c-myc encodes a tran-
scription factor that plays a critical role in an epigenetic man-
ner [32] over a broad range of cellular processes, including 
cell cycle progression, cell growth, differentiation, transforma-
tion, angiogenesis, apoptosis and chemoresistance [33].  
Albeit modulation of c-Myc might enhance the response 
of cisplatin against MPM and possibly modulate its 
chemoresistance, targeting c-Myc causes heavy systemic 
effects in healthy tissues with high proliferative index [34]. 
However, c-Myc modulation can be selectively induced in 
cancer cells targeting the BET subfamily of bromodomain 
(BRD)-containing proteins. In particular, BRD4 is a ubiqui-
tous transcription co-factor, associated with oncogenes, 
whose transcription is ruled by super-enhancers [35]. Super-
enhancers need an excess of transcription, rendering the gene 
very sensitive to BRD4 inhibition. Since the survival of 
transformed cells depends on oncogenes, their depletion in-
duces death preferentially in cancer cells, while preserving 
somatic ones [36]. BRD4 controls genes involved in cell 
proliferation, cell cycle progression, oxidative stress re-
sponse, inflammation, and DNA repair [37]. These pathways 
are all deregulated in MPMs [38]. 
BET inhibitors are gaining increasing attention and some 
of them entered clinical trials [37]. Furthermore, they 
showed strong anti-inflammatory effects [39]: as far as im-
mune-based therapies are gaining increasing attention for the 
treatment of mesothelioma [40], BET inhibitors could repre-
sent both anticancer and anti-inflammatory therapeutic ap-
proach. Thus, BRD4 inhibition could be a promising strategy 
against this kind of cancer.  
JQ1, a thienodiazepine derivative, was developed as a 
specific BRD4 inhibitor [41, 42] and showed encouraging 
antitumor activity both in vitro and in vivo. It leads to repres-
sion of c-Myc and of c-Myc target genes by abrogating re-
cruitment of enhancer complexes [43]. Combination of JQ1 
and cisplatin resulted synergistic on animal models of ovar-
ian cancer both in vitro and in vivo, [44] and showed similar 
effects on other cancer types [45, 46]. Furthermore, JQ1 en-
hances apoptosis induction in cisplatin-resistant cells [47].  
Furthermore, JQ1 increases HO-1 [48], and BRD4 inhibi-
tion enhances the ATM-dependent DNA damage signaling 
and triggers DDR [49, 50].  
Marked differences in JQ1 sensitivity correlate to modula-
tion of another BRD4 target gene: Fra-1, also known as FOSL1 
[51]. Fra-1 is an oncogenic transcription factor belonging to the 
Fos subfamily, that dimerize with Jun proteins to form AP-1, a 
transcription factor involved in mesothelial transformation [52]. 
AP-1 and c-Myc stimulate transcription of genes encoding pro-
teins that promote progression through the G1 phase of the cell 
cycle and the G1 to S transition [53,54], and inhibit CDK inhibi-
tor p21, mainly regulating its p53-directed transcription [55, 56]. 
Increased levels of p21 can lead to a permanent growth arrest, 
i.e. cellular senescence [57], and can be induced by both cis-
platin [58-60] and JQ1 [61-64]. 
JQ1 induces p21 also in a p53-independent way, i.e. 
LATS1/YAP signaling inhibition [64]. YAP plays the central 
role of the Hippo pathway, a promising target for MPM ther-
apy [65]. YAP induces c-Myc transcription, but c-Myc itself 
inhibits YAP, hence downregulated c-Myc could increase 
YAP-target genes transcription [66], as BIRC5/survivin [67], 
an inhibitor of apoptosis (IAP) member. On the other side, 
this gene can be inhibited by p21 along with p53 [57]. Sur-
vivin regulates tumor cell apoptosis via its interaction with 
XIAP [68], another BET target, that decreases upon JQ1 
treatment [45].  
Thus, JQ1 could decrease the antiapoptotic armory in MPM 
cells and lower the chemoresistance as well. With this goal, we 
investigated if JQ1 is able to inhibit MPM growth and thus, 
playing a role in combination chemotherapy of MPM. 
2. MATERIALS AND METHODS  
All compounds were tested on three MPM cell lines, called 
BR95 (epithelioid), MG06 (mixed or biphasic, with epithe-
lioid predominance), MM98 (sarcomatoid), and a cisplatin-
resistant cell line called MM98R. All cell lines were obtained 
from the biobank of the Hospital of Alessandria [10] and were 
routinely tested for mycoplasma contamination.  
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BR95 and MG06 cells were grown in F10 Ham medium, 
while DMEM was used for sarcomatoid cells. Media were 
supplemented with L-glutamine 2 mM, penicillin 100 IU 
mL-1, streptomycin (100 mg L-1) and 10% FBS, and cells 
were cultured at 37 °C in a 5% CO2 humidified chamber.  
2.1. Drug Screening Assays 
A quantity of 2-5 × 103 cells per well were seeded onto 
black sterile tissue-culture treated 96-well plates (CulturPlate 
96 F, Perkin Elmer, Milan) and allowed to attach 24 hours 
before drug treatment. 
Cisplatin was dissolved in 0.9% (w/v) NaCl aqueous so-
lution brought to pH 3 with HCl (final stock concentration 1 
mM). JQ1 was dissolved in DMSO to final concentration 10 
mM. The final DMSO concentration never exceeded 0.5% 
(non-toxic concentration).  
Combination experiments were carried on using fixed 
dose ratio protocols [69]. For simultaneous administration, 
cisplatin and JQ1 mother solutions were co-diluted (at molar 
ratio 1:10 for MM98 and MM98R cell, and at molar ratio 1:3 
for BR95 and MG06, according to their relative drug sensi-
tivity) and the resulting stock solution was serially diluted to 
a range of three orders of magnitude of concentrations and 
administered to cells.  
Challenges were performed for 72 hours continuous treat-
ment (CT). Residual cell viability was evaluated by means of 
the resazurin reduction assay, as previously reported [70]. 
Fluorescence was measured using an excitation wavelength of 
550 nm and an emission wavelength of 585 nm with a Tecan 
Infinite F200Pro plate reader (Tecan Austria). 
In each experiment, cells were challenged with the drugs 
at different concentrations and the final data were calculated 
from at least three replicates of the same experiment carried 
out in triplicate. The fluorescence intensities of 8 wells con-
taining medium without cells were used as background value 
to be subtracted. Data were normalized to 100% cell viability 
for non-treated cells; IC50 (half inhibitory concentration) was 
obtained from the dose-response sigmoid using Origin Pro 
(version 8, Microcal Software, Inc., Northampton, MA, 
USA). Data presented were calculated from at least three 
replicates of the same experiment carried out in triplicate.  
The combination index (CI) was calculated for non-
mutually exclusive drugs, according to the following equa-
tion: 
 
 
 
where Dx1 and Dx2 were the concentrations required for a 
given effect (the same residual cell viability e.g. 50% growth 
inhibition, IC50) respectively for drug 1 and 2 alone, while 
D1 and D2 were the concentrations required for the same 
effect for drug 1 and 2 in a combination experiment. CI val-
ues below 1 indicated synergism, equal to 1 additive effect, 
and higher than 1 antagonism [71]. 
2.2. Immunoblot Analysis  
BR95 and MG06 were treated with 2.5 µM JQ1, and/or 
with cisplatin at molar ratio 1:3, while MM98 and MM98R 
were treated for 24 h with 0.25 µM JQ1 and/or with cisplatin 
at molar ratio 1:10. Then, cells were lysed in RIPA buffer 
(50 mM Tris–HCl, 150 mM NaCl, 1% Igepal CA-630, 0.1% 
SDS, pH 8) supplemented with protease inhibitor cocktail 
(Sigma-Aldrich); after 3 cycles of freeze-thawing, cell debris 
were removed by centrifugation. Protein concentration was 
determined using the bicinchoninic acid method (BCA assay, 
Pierce Biotechnology). A total of 10 µg of proteins were run 
on a 10% SDS–PAGE, then blotted onto a PVDF membrane 
(Immobilon-P, Millipore, MA, USA), blocked with 3% w/v 
non-fat milk, and finally detected by Mouse anti c-Myc pri-
mary antibody (9E10: sc40, diluted 1:200), rabbit anti Fra-1 
(R-20: sc-605, diluted 1:200), and mouse anti actin (C-2: sc-
8432, diluted 1:200), and HRP-conjugated anti-mouse and 
anti-rabbit antibodies (sc-2005 and sc-2004, diluted 1:2000 
and 1:5000, respectively). All antibodies were purchased 
from Santa Cruz Biotechnology. Blots were developed with 
ECL reagent (Sigma-Aldrich), using a ChemiDoc apparatus 
(Bio-Rad). Each experiment was repeated at least twice. 
A549 lung adenocarcinoma cells were used as positive con-
trol for the immunoblot analyses. 
2.3. Cell Cycle Analysis 
After the treatments performed as above, cells were fixed 
in 70% cold ethanol, and stored at -20°C. Before the analy-
sis, cells were treated with 20 µg/ml RNAse A in PBS (for 
30 min at room temperature), then diluted to 5x105 cells/ml 
in PBS containing 50 µg/ml propidium iodide (PI). Flow 
cytometric analyses were performed with a Partec CyFlow 
Space (Partec GmbH, Muenster, Germany). Data were ana-
lyzed with the CyFlogic v 1.1.1. Data from two independent 
experiments, performed in duplicate, were compared to un-
treated control by means of a chi-squared test (* p<0.05; ** 
p<0.01; *** p<0.001). 
2.4. Single Cell Gel Electrophoresis (SCGE), or Comet 
Assay 
Cells were challenged with the drugs for 24 hours with 
the same concentrations as above. H2O2 was used as positive 
control (0.7 mM, 5 min treatment). A total of 250 × 103 cells 
were mixed with an equal volume of 0.5% Low melting 
point agarose (LMA), and deposed onto the precoated slides 
with 1% normal melting point agarose (NMA). A final layer 
of LMA was added. Cell lysis was performed in 2.5 M NaCl, 
100 mM EDTA, 10 mM Tris, 1% Triton X-100, pH 10 for 1 
hour at 4 °C. Slides were then washed with water, and trans-
ferred to an electrophoresis tank for 10 min at room tempera-
ture in 300 mM EDTA, 300 mM NaOH, pH 13.0; then, a 10 
min electrophoretic run (300 mA, 25 V) was performed [72]. 
Slides were neutralized with PBS, air-dried and fixed in 
ethanol. All buffers were freshly prepared prior use. 
Nuclei were stained with 0.2 µg/ml DAPI. Digital images 
of the nuclei were recorded at 40X magnification (Axiocam 
and Axiovert, Carl Zeiss Inc., Thornwood, NY).  
Three independent replicates were performed and a total 
of 50 cells were scored for each sample.	  The captured images 
were analyzed for the % DNA in tail (TI) with TriTek Com-
etScore™. For each treatment, log-transformed TI  values 
were compared to control by means of a two-sample t-test. 
Data (i.e. the median values, back-transformed to TI) were 
normalized versus the control, to calculate the fold-change, 
according to current guidelines [73]. 
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2.5. Apoptosis: Caspase-3/7 Activity 
The human ovarian carcinoma cell line A2780 was used 
as positive control for apoptosis induction [74] and the assay 
was performed similarly to a previous report [75]. A2780 
cells were treated with 10 µM cisplatin or the same sched-
ules as above. 1x104 cells were seeded in 96-well tissue cul-
ture (TC) plates in complete medium, the day before treat-
ment, performed with the same concentrations as above (and 
lower). After 24h, cells were washed, and lysed with 25 µL 
of lysis buffer (10 mM HEPES, 2 mM EDTA, 2 mM DTT, 
0.1 % CHAPS, pH 7.4). The caspase 3/7 inhibitor Ac-
DEVD-CHO 0.01 g/L (Sigma-Aldrich) was added to control 
wells. Then, 200 µL the caspase-3 fluorescent substrate, Ac-
DEVD-AFC (Sigma-Aldrich), 0.01 g/L in lysis buffer, was 
added to all wells. A volume of 200 µL of each sample was 
transferred to a black microtiter plate and the activity was 
followed for 1 hour by means of fluorescence at Exc. 390/ 
Em. 520 nm, normalized versus the blank. Final fold activity 
(with respect to control wells) was calculated as the mean of 
at least three independent replicates performed in duplicate 
for each condition.  
2.6. Detection of Cellular Senescence: Senescence-
associated (SA) β-galactosidase Staining 
The SA-β-galactosidase staining was performed as previ-
ously described [76]. BR95 and MG06 were treated with 0.5, 
1 and 2.5 µM JQ1, and/or with cisplatin at molar ratio 1:3 
MM98 and MM98R were treated with 0.05, 0.1 and 0.25 µM 
JQ1 and/or with cisplatin at molar ratio 1:10. After 3 days, a 
set of experiments was stopped by means of fixation in 3% 
formaldehyde, while drug-free fresh medium was given to a 
parallel set, and left until the 7th day. At least three different 
10X microscopic fields per well were photographed (Leica 
EC3 camera mounted on a Leica DMIL LED microscope), 
and the total number of cells and the blue ones was counted 
with the Cell Counter plug-in of ImageJ 1.45s.  
2.7. 3D-spheroid Mesothelioma Model 
Spheroids were adopted since they simulate better the dif-
fusion gradient of drugs, O2 and nutrients [77]. They were 
prepared following a previously published protocol [78]. 
Briefly, BR95 cells at 104 /well density were seeded in U-
shaped 96-well polypropylene plates, and incubated on an 
orbital mixer in a standard culture incubator. After 4 days, 
spheroids of 300-400 µm diameter were obtained. Cisplatin 
was given for 24h, and then spheroids were treated with JQ1 
for further 3 + 3 days. Control experiments were carried out 
with drug-free medium. On day 4 and 7 of treatment (corre-
sponding to day 8 and 11 from cell seeding, day 0) were taken 
pictures of at least three spheroids per each experimental con-
dition were taken at 4X magnification and the dimensions of 
spheroids were assessed using the Leica Application Suite 
software (v. 2.0). The spheroid volume was calculated from 
the mean diameter, and reported as fold change with respect to 
the time zero of the treatment. 
2.8. Quantitative Real-time PCR (qPCR) 
Total RNA was extracted by means of a kit (GenElute 
MAMMALIAN TOTAL RNA MINIPREP KIT), followed 
by DNAse treatment (DNAse I) (Fermentas, St. Leon-Rot, 
Germany). Then, 1 µg RNA was retrotranscribed in cDNA 
with the RevertAid™ H Minus First Strand cDNA Synthesis 
Kit (Thermo-Fisher) using the random primers. Each gene 
expression was normalized on the housekeeping gene ribo-
somal 18S rRNA. Assays were performed in triplicate for 
each treatment in a 20 µl reaction volume containing 1 µl of 
RT products, 10 µl Sso-Fast EVA Green SMX (Bio-Rad), 
500 nM each forward and reverse primers, to detect c-Myc, 
Fra-1, Fos, HO-1, ATM, GADD45A, BIRC Surv, p21, 
p53,APAF-1, DAPK1, XIAP, as indicated in Table S1.  
An automated CFX96 real-time thermocycler was used 
(Bio-Rad). The reaction conditions were 95°C for 1 minute, 
followed by 45 cycles 98°C for 5 seconds and anneal–extend 
step for 5 seconds at 60 °C, with data collection. At the end 
of these cycles, a melting curve (65°C to 95°C, with plate 
read every 0.5°C) was performed in order to assess the speci-
ficity of the amplification product by single peak melting 
temperature verification. Results were analyzed with Bio-
Rad CFX Manager and exported to Excel (Microsoft, 
Redmond, WA, USA) for calculation and statistical analyses. 
3. RESULTS AND DISCUSSION  
3.1. JQ1 Enhances Cisplatin Cytotoxicity Inducing Apop-
tosis and Growth Arrest in MPM Cells  
The MPM cells were challenged with JQ1 or cisplatin to 
observe the relative chemosensitivity (Table 1). Among the 
different MPM phenotypes, MM98 and MM98R cells were 
the most sensitive to JQ1, with negligible difference for the 
cisplatin-resistant cell line, as previously observed for other 
cancer types [47].  
We performed drug combination studies, employing cis-
platin and JQ1 at fixed molar ratio, i.e. 10:1 on sarcomatoid 
cells and 3:1 on epithelial and mixed cells, chosen according 
to their IC50 values.  
As shown in Fig. 1A-C, the drug combination was al-
ways more active than cisplatin alone, and resulted synergis-
tic on MG06 (CI<1, Fig. 1A and 1B), partially synergistic on 
MM98 (Fig. 1C and 1D), and additive on the remaining 
MPM cells (Fig. 1E-H, CI around 1). Thus, drug synergism 
did not rely on cellular MPM phenotype and was unrelated 
to the cell-line chemosensitivity. 
Superadditivity was observed after 3 days of treatment, 
based on residual viability, which depends on cell death and 
growth inhibition. Both phenomena occur at earlier time, 
thus we performed the specific assays after 24 hours of 
treatment with IC50-value concentrations: BR95 and MG06 
were treated with 2.5 µM JQ1, and/or with cisplatin at molar 
ratio 1:3, while MM98 and MM98R were treated with 0.25 
µM JQ1 and/or with cisplatin at molar ratio 1:10. 
 Caspase 3/7 is the central player of both intrinsic and 
extrinsic apoptotic pathways, leading to cell death. As shown 
in Fig. (2), while cisplatin had negligible effect, JQ1 induced 
significant caspase-3/7 activation in all MPM cell lines. The 
combination further increased apoptosis in MG06 and 
MM98, correlating with the observed synergism. Thus, inde-
pendently on the cellular chemosensitivity, JQ1 showed a 
remarkable pro-apoptotic activity.  
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Table 1.  IC50 values (intended as µM concentrations) obtained after 72h of treatment. Resistance Factor, RF = IC50 MM98R / IC50 
MM98. Data are means ± standard deviation of at least 3 replicates.a Data previously published [9]. 
 BR95 MG06 MM98 MM98R  
	   IC50(µM)	   RF	  
JQ1 2.2±0.6 1.0±0.3 0.089 ±0.023 0.18±0.08 2.0 
cisplatin 6.2±0.9 4.1±1.5	  a 3.2±1.0	  a 19.4±2.8	  a 8.1	  a	  
 
 
Fig. (1). Pharmacological interaction of JQ1 and cisplatin. Each 
row shows on the left the concentration-response graph of the cells 
challenged with cisplatin only (solid line) or cisplatin and JQ1 (dot-
ted line). On the right, the combination index (CI) value computed 
for the same levels of residual viability is shown (A),(B): MG06; 
(C), (D): MM98; (E), (F): MM98R; (G), (H): BR95. Data are 
shown as the mean ± standard deviation of at least 3 replicates for 
each experiment. 
 
Fig. (2). Apoptosis induction after 24 h treatments. The positive 
control, A2780 cells, were treated with 10 µM cisplatin. Data are 
shown as Caspase 3/7 fold-change activity of treated cells over the 
untreated control (black filled bars), after cisplatin (grey bars), JQ1 
(light grey bars), or the combination of both (white bars). Data are 
shown as the mean ± standard deviation. The statistic determination 
was computed versus the untreated control by means of two-sample 
t-test (p<0.05; ** p<0.01; *** p<0.001). 
 
Cell cycle analyses gave contrasting results: as shown in 
Fig. (3), JQ1 had negligible effect on BR95 and MG06 cell 
cycle distribution, while induced G1 arrest in the most sensi-
tive MM98 and MM98R, as expected. Cisplatin increased 
the S phase in BR95, MG06 and MM98, but not MM98R. G2 
increased in MM98 only. Since successful DSB repair in-
volves HR, a backup-copy of DNA, represented by a sister 
chromatid is essential; thus, HR is restricted to late S and G2 
phases of the cell cycle, as usually observed in cisplatin-
treated cells [5].  
Combination treatment allowed cells to recover the same 
pattern as the control, except MG06 and, partially, BR95, 
where the same pattern caused by cisplatin was observed 
(p>0.05).  
We also observed late effects of the treatments on MPM 
cellular growth. The SA β-galactosidase staining was per-
formed both after 3 days of treatment (T), and after further 4 
days of recovery (R) in drug-free medium (3-T and 4-R, 
(Fig. 4) left and right, respectively). The combination be-
tween JQ1 and cisplatin induced the highest percentage of 
senescence, both after 3-T and after additional 4-R. Few se-
nescent cells (<20%, Fig. 4G-H) were observed in MM98R 
after all treatments. The withdrawal of treatments (4-R) re-
duced senescent cells, in MM98 in more evident manner 
(Fig. 4F). Thus, growth inhibition needed a prolonged expo-
sure.  
Since cisplatin is usually given as a bolus injection or as 
infusions varying from 1 hour to 24 hours [79], while a pro-
longed JQ1 treatment is safe [80], we tested a schedule 
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Fig. (3). Cell cycle distribution after 24 hours treatment of (A) MG06; (B) BR95; (C) MM98; (D) MM98R. Stacked columns represent the % 
of cells attributed to each cell cycle phases (dark grey: G1, light grey: S, white: G2/M). Data are shown as the mean ± standard deviation, and 
compared to untreated control by means of a chi-squared test (* p<0.05; ** p<0.01; *** p<0.001). 
 
consisting of prolonged treatment with JQ1 after cisplatin. 
When BR95 spheroids were challenged with cisplatin for 24 
hours and with JQ1 for further 6 days, strong volume de-
crease was observed even at low micromolar concentrations 
of both drugs, as shown in Fig. 5 and Fig. S1. 
Data show that cisplatin activity on MPM is mainly anti-
proliferative: it induces no apoptosis (Fig. 2), but S phase	  
cell cycle arrest (Fig. 3) and cellular senescence (Fig. 4), 
except for the cisplatin-resistant sub-line, MM98R. On the 
contrary, JQ1 is proapoptotic in all MPM cell lines, with a 
modest antiproliferative activity. Apoptosis induction may be 
the mechanism underlying the observed superadditivity. 
3.2. The Role of BRD4-related Pathways 
JQ1 activity on cancer cells has been mainly attributed to 
c-Myc 41 or to FOSL1 47 decrease. Thus, these BRD4 target 
proteins were quantified by immunoblotting (Fig. 6). As ex-
pected, JQ1 decreased c-Myc expression in all MPM models, 
except for the cisplatin-resistant cell line MM98R, where a 
cisplatin-induced increase of c-Myc was observed (Fig. 6A). 
The simultaneous treatment with JQ1 reversed this trend, as 
it downregulated c-Myc in all MPM cells (Fig. 6B). 
As Fig. (6A) shows, A549 lung cancer cells were used as 
positive control for the immunoblot and gave an intense band 
around 40 kDa, and a faint band around 30 kDa (Fig. 6C), 
assigned to the phosphorylated and the unmodified protein, 
respectively. Only the latter band was observed in MPM. 
The expression of Fra-1 decreased in epithelial-like cells 
(MG06 and BR95) after JQ1 and combination treatment 
(Fig. 6C). Thus, Fra-1 downregulation could somewhat con-
tribute to the chemosensitization activity of JQ1. 
The pattern of expression of the two c-Myc and Fra-1 
transcripts was assayed by means of qPCR, along with other 
BRD4-related target genes. 
As shown in Fig. (7), c-Myc mRNA decreased on all cell 
lines after JQ1 treatment, but not in MM98 and MM98R 
after cisplatin treatment, as observed for the expressed pro-
teins. Furthermore, the combination induced a slight increase 
of c-Myc mRNA expression. Thus, while JQ1 showed a ca-
nonical c-Myc decrease on epithelial-like cells BR95 and 
MG06, it had contrasting effects on c-Myc levels on the sar-
comatoid MPM cells.  
Fra-1 expression dropped in all cell lines after JQ1 treat-
ment, except for the cisplatin-resistant sub-line MM98R, and 
for the combination with cisplatin, that induced a Fra-1 in-
crease in both MM98 and MM98R. 
As shown in Fig. (7), Fos expression varied independ-
ently on Fra-1 in a cell-line-dependent fashion, with an evi-
dent reduction in MM98 and an increase in the epithelioid 
cell lines (BR95 and MG06). 
3.3. The Role of p53 and p21 
As expected, low levels of c-Myc and Fra-1 induced p53 
and p21 expression after cisplatin treatment in all MPM cell 
lines (Fig. 7). On the contrary, JQ1, both alone and in combi-
nation, induced p21 increase along with p53 decrease, as pre-
viously observed in other types of cancer [81] Upregulated 
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Fig. (4). Cell senescence was determined as the % of SA-β-gal positive (senescent) cells. Data are presented as the mean ± standard deviation 
of two independent replicates. The left side shows the assay performed after 3 days of treatment, while the right side shows the assay per-
formed after further 4 days of recovery. From top to bottom: (A), (B): MG06; (C), (D): BR95; (E), (F): MM98; (G), (H): MM98R. Cisplatin 
(concentration given in the top axis): back filled circles; JQ1 (concentration given in the bottom axis): filled squares; cisplatin+JQ1: white 
squares. 
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Fig. (5). BR95 spheroids growth inhibition. (A) treatment with cisplatin for 1 day, followed by drug-free medium for 3+3 days. (B) treatment 
with drug-free medium for 1 day, followed by JQ1 for 3+3 days (C) treatment with cisplatin for 1 day, followed by JQ1 for 3+3 days. 
 
 
Fig. (6). Expression of target proteins c-Myc and Fra-1 after 24 h treatments. (A) Representative immunoblots for c-Myc, Fra-1 and loading 
control (actin). (B) log2 fold increase of c-Myc with respect to the untreated control. (C) log2 fold increase of Fra-1 with respect to the un-
treated control after cisplatin (grey bars), JQ1 (light grey bars), or the combination of both (white bars). Data are shown as the mean ± stan-
dard deviation. 
 
p21 correlated with senescence induction, showing the maxi-
mal effect after the combination treatment (Fig. 4). p21 levels 
were increased in cells where JQ1 induced G1 arrest, namely 
MM98 and MM98R (Fig. 7 and Fig. 3 C-D), as previously 
reported [47].  
Downstream genes as BIRC5/survivin were actually 
modulated by JQ1, and by cisplatin, with cell-line-specific 
patterns (Fig. 7). Furthermore, following JQ1-based treat-
ments, all MPM cell lines showed decreased XIAP tran-
script, except MM98R and cisplatin-treated BR95 cells.  
The pattern of expression of p53, XIAP and APAF-1 
were similar in all MPM cell lines, except for BR95 cells, 
that express a mutant p53 protein [5,82]. APAF-1 expression 
was marginally affected by cisplatin treatment, and increased 
in BR95 and MM98R; on the contrary, JQ1 and its combina-
tion decreased APAF-1 in MM98 and MG06 cells, where 
synergism was observed (Fig. 1).  
Therefore, in MPM cells JQ1–induced apoptosis mostly 
relied on c-Myc downregulation rather than that of p53. JQ1 
and/or its combination treatment favored apoptosis induction 
modulating proapopototic (APAF-1, DAPK) and antiapop-
totic genes (IAPs). 
3.4. The Role of DNA Damage and Repair  
As expected, ATM and c-Myc expression exhibited a 
similar pattern in all MPM cell lines (Fig. 7). The increased 
expression of HO-1 likely activated ATM, except in MM98 
cells (Fig. 7). 
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Fig. (7). qPCR measure of expression levels of selected target genes, after a 24 hours treatment. Bars represent the log2 fold increase versus 
the untreated control (dark grey: cisplatin, light grey: JQ1, white: combination). (A) MG06; (B) BR95; (C) MM98; (D) MM98R. Bars repre-
sent mean values ± standard deviation. 
 
 
Fig. (8). DNA breaks induced by the treatments. Data are shown as 
the mean + standard deviation of fold median TI variation, versus 
the untreated control, represented by the horizontal line at value 1. 
Filled squares: cisplatin; filled circles: JQ1; open triangles cis-
platin+JQ1; filled stars: positive control (H2O2).  
 
ATM activates p53, a central protein in apoptosis induc-
tion, cellular senescence and DNA repair.  
The p53-dependent apoptotic checkpoint relies on 
DAPK1, and it is turned on by c-Myc [25]. Accordingly, the 
pattern of expression of DAPK1 and p53 were similar to that 
of c-Myc after JQ1-based treatments (Fig. 7).  
p53 rules the expression of GADD45 [22], which stimu-
lates NER [83]. GADD45 was upregulated by cisplatin 
treatments, except in the resistant cell line MM98R (Fig. 7), 
probably due to increased tolerance to Pt-DNA adducts. 
However, except in p53-defective BR95 cells, JQ1 alone or 
its combination treatment induced GADD45 expression.  
As previously stated, Pt-DNA adducts are processed to 
SSBs and to DSBs. Accumulation of DNA breaks suggests 
tolerance to Pt-DNA adducts or uncompleted damage proc-
ess. The comet assay should evidence such DNA breaks. As 
(Fig. 8 and Fig. S2) shows, cisplatin induced a biologically 
relevant increase of DNA breaks (≥3 fold over control) in 
MM98 cells, indicating that active removal of DNA-Pt ad-
ducts was followed by uncompleted DNA repair. Accord-
ingly, only MM98 cells showed G2 phase increase after cis-
platin treatment (Fig. 3C), pointing out uncompleted DSB 
repair through HR. DNA breaks accumulation may explain 
the high cisplatin-sensitivity of these cells (Table 1). Since 
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MM98 cells did not upregulate HO-1 expression (Fig. 7), 
they were less able to induce an ATM-dependent DDR and 
proficient DNA repair. Senescence is a hallmark of the 
DDR-induced cellular fates [77,80]. Accordingly, treatment 
withdrawal (4-R) (Fig. 4F) reduced cellular senescence in 
MM98 cells only, pointing out decreasing DDR signaling.  
On the other hand, the other MPM cell lines increased 
HO-1 expression (Fig. 7), showed relevant levels of senes-
cence (Fig. 4).  
JQ1 reduced cisplatin-induced DNA breaks in MM98 
and MM98R cells, and significantly reduced (p<0.01) basal 
DNA breaks in all MPM cells. These data are in tune with 
previous reports that showed that JQ1-dependent BRD4 in-
hibition enhances the ATM-dependent DNA damage signal-
ing and triggers DDR [73,74].  
CONCLUSION 
The BET inhibitor JQ1 and cisplatin showed additive/ 
superadditive efficacy on MPM cellular models. Their	  mechanisms	  of	   action	   complemented	   each	   other.	   In	   fact,	  
JQ1 was able to enhance cisplatin activity by means of c-
Myc downregulation. The consequent DDR enhancement 
lead to apoptosis induction and/or permanent growth arrest 
(senescence), depending on the MPM cellular context.	  	  
Both cellular fates represent a permanent antitumor ef-
fect, leading to tumor regression, at least in the 3D in vitro 
model. Thus, the pharmacological modulation of BET activ-
ity could represent a promising tool for future MPM therapy. 
LIST OF ABBREVIATIONS 
AP-1 = Activator Protein-1 
APAF-1 = Apoptotic protease activating fac-
tor 1 
ATM = Ataxia-telangiectasia mutated gene 
BET = Bromodomain and extraterminal 
BIRC5 = Baculoviral IAP Containing Pro-
tein 5 
BRD = Bromodomain 
CDK = Cyclin-dependent kinase 
CI = Combination index 
cisplatin = Cis-
diamminedichloridoplatinum(II) 
CO = Carbon monoxide 
CT = Continuous treatment 
DAPK-1 = Death-associated protein kinase 
DDR = DNA Damage Response 
DMEM = Dulbecco Modified Eagle’s Me-
dium 
DSB = Double strand breaks 
FBS = Fetal bovine serum 
FOSL1 = FOS-Like antigen 1 
GADD45/GADD45A = Growth arrest- and DNA damage-
inducible gene A 
HO-1 = Haem Oxygenase 1 
HR = Homologous recombination 
IAP = Inhibitor apoptosis 
IC50 = Half inhibitory concentration 
JQ1 = (+)-JQ1, namely S)-tert-butyl 2-(4-
(4-chlorophenyl)-2,3,9-trimethyl-
6H-thieno[3,2-f][1,2,4]triazolo[4,3-
a][1,4]diazepin-6-yl)acetate 
LATS1 = Large Tumor Suppressor 1 
LMA = Low melting point agarose  
MPM = Malignant Pleural mesothelioma 
NER = Nucleotide Excision Repair 
NHEJ = Non-homologous end joining 
NMA = Normal melting point agarose 
NRF2 = NFE2 related factor 
p21 = p21WAF1/Cip1  
PI = Propidium iodide 
PVDF = Polyvinylidene fluoride 
qPCR = Quantitative real-time PCR 
RIPA = Radio immune-precipitation assay 
ROS = Reactive oxygen species 
RT = Retrotranscription 
SA-β-galactosidase  = Senescence-associated (SA) β-
galactosidase 
SCGE = Single cell gel electrophoresis 
SDS = Sodium dodecyl sulfate 
SSB = Single strand breaks 
TC = Tissue Culture 
TI = Tail Intensity 
YAP = Yes Associated Protein 
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